[ad_1]
DUBLIN – (BUSINESS WIRE) – July 2, 2018 – The report "Transthyretin Amyloidosis (ATTR) – Epidemiology Forecast to 2027" has been added to the ResearchAndMarkets.com offering.
The epidemiology of the disease The report provides historical and predictive epidemiology (prevalent cases diagnosed, specific diagnosed prevalent cases, treatable cases, and carpal tunnel syndrome surgery cases related to ATTR). Scenario of transthyretin amyloidosis in the 7MM covering the United States and the EU5 (Germany, Spain), Italy, France and the United Kingdom) and Japan from 2016 to 2027
The report also provides the epidemiological trends observed in the 7MM during the study period, as well as the badumptions made. The calculated data are presented with relevant charts and graphs to give a clear view of epidemiology at first glance.
According to this research, the total population diagnosed for transthyretinic amyloidosis (ATTR) was established at 19,160 in 2016
Report: Detailed overview of transthyretinic amyloidosis explaining its causes, its symptoms, clbadification, physiopathology, diagnosis and treatment regimens. The report provides an overview of the history and expected number of patients with transthyrinic amyloidosis in 7 patients. The report badesses the risk and burden of the disease and highlights the unmet needs of the disease. The report helps to recognize growth opportunities in the 7MM compared to the patient population. The report provides the segmentation of the epidemiology of the disease by type ie, hereditary [FAP (FAP Stage 0, I,II,III) & FAC] and non-hereditary cases of ATTR in 7MM
Results:
Segmentation of patientsDiseaseDisease Risk & BurdenRisk of the disease by segmentationFactors of growth in a specific patient population
Main topics:
1. Main ideas
2. Background and Overview of Disease: Transthyretin Amyloidosis (ATTR)
3. Epidemiology and patient population
4. Pediatric epidemiology of transthyretinic amyloidosis (ATTR)
5. Surgical Cases Diagnosed with ATTR Receptor Carpal Tunnel Syndrome
6. Appendix
7. Capacities
8. Disclaimer
9. About the Publisher
For more information on this report, visit https://www.researchandmarkets.com/research/w3flzh/global?w=4
View the source version at businesswire.com:https://www.businesswire.com/news/ home / 20180702005413 / en /
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Director
For Eastern office hours, dial 1-917-300-0470
For free call US / CAN 1-800-526-8630
For GMT office hours Call + 353- 1-416-8900
Related Topics: Drugs of the Central Nervous System, Drugs for Endocrine and Metabolic Disorders [19659022] KEY WORDS:
KEY WORDS FOR INDUSTRY: PHARMACEUTICAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 07/02/2018 06:12 AM / DISC: 07/02/2018 06:12 AM
http://www.businesswire.com/news / home / 20180702005413 / en
Copyright Business Wire 2018.
Source link
